Nardone Valerio, Belfiore Maria Paola, De Chiara Marco, De Marco Giuseppina, Patanè Vittorio, Balestrucci Giovanni, Buono Mauro, Salvarezza Maria, Di Guida Gaetano, D'Angiolella Domenico, Grassi Roberta, D'Onofrio Ida, Cimmino Giovanni, Della Corte Carminia Maria, Gambardella Antonio, Morgillo Floriana, Ciardiello Fortunato, Reginelli Alfonso, Cappabianca Salvatore
Department of Precision Medicine, University of Campania "L. Vanvitelli", 80138 Naples, Italy.
Radiotherapy Unit, Ospedale del Mare, ASL Napoli 1 Centro, 80138 Naples, Italy.
Diagnostics (Basel). 2023 May 12;13(10):1717. doi: 10.3390/diagnostics13101717.
Non-small-cell lung cancer (NSCLC) is a common, steady growing lung tumour that is often discovered when a surgical approach is forbidden. For locally advanced inoperable NSCLC, the clinical approach consists of a combination of chemotherapy and radiotherapy, eventually followed by adjuvant immunotherapy, a treatment that is useful but may cause several mild and severe adverse effect. Chest radiotherapy, specifically, may affect the heart and coronary artery, impairing heart function and causing pathologic changes in myocardial tissues. The aim of this study is to evaluate the damage coming from these therapies with the aid of cardiac imaging.
This is a single-centre, prospective clinical trial. Patients with NSCLC who are enrolled will undergo computed tomography (CT) and magnetic resonance imaging (MRI) before chemotherapy 3 months, 6 months, and 9-12 months after the treatment. We expect to enrol 30 patients in 2 years.
Our clinical trial will be an opportunity not only to highlight the timing and the radiation dose needed for pathological cardiac tissue changes to happen but will also provide useful data to set new follow-up schedules and strategies, keeping in mind that, more often than not, patients affected by NSCLC may present other heart- and lung-related pathological conditions.
非小细胞肺癌（NSCLC）是一种常见的、呈稳定增长态势的肺部肿瘤，常在无法采用手术治疗时被发现。对于局部晚期不可切除的NSCLC，临床治疗方法包括化疗和放疗联合应用，最终可进行辅助免疫治疗，这种治疗虽有效果，但可能会引起多种轻度和重度不良反应。具体而言，胸部放疗可能会影响心脏和冠状动脉，损害心脏功能并导致心肌组织发生病理变化。本研究的目的是借助心脏成像技术评估这些治疗所造成的损害。
这是一项单中心前瞻性临床试验。入组的NSCLC患者将在化疗前、治疗后3个月、6个月以及9至12个月接受计算机断层扫描（CT）和磁共振成像（MRI）检查。我们预计在两年内招募30名患者。
我们的临床试验不仅将有机会明确病理性心脏组织变化发生所需的时间和辐射剂量，还将提供有用的数据以制定新的随访计划和策略，要记住的是，NSCLC患者往往可能存在其他与心脏和肺部相关的病理状况。
